Opportunities and challenges of circulating biomarkers in neuroblastoma
Molecular analysis of nucleic acid and protein biomarkers is becoming increasingly common in paediatric oncology for diagnosis, risk stratification and molecularly targeted therapeutics. However, many current and emerging biomarkers are based on analysis of tumour tissue, which is obtained through i...
Main Authors: | Ricky M. Trigg, Jacqui A. Shaw, Suzanne D. Turner |
---|---|
Format: | Article |
Language: | English |
Published: |
The Royal Society
2019-05-01
|
Series: | Open Biology |
Subjects: | |
Online Access: | https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.190056 |
Similar Items
-
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma
by: Seema Chugh, et al.
Published: (2025-02-01) -
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
by: J. Guan, et al.
Published: (2016-09-01) -
Identification of Contactin-1 as a Potential Biomarker and Therapeutic Target in Neuroblastoma
by: Christa N. Grant, et al.
Published: (2024-11-01) -
Molecular Heterogeneity in Neuroblastoma and Its Clinical Significance
by: Tekincan Çağrı Aktaş, et al.
Published: (2023-08-01) -
Enhancer of zeste homolog 2 regulates cell differentiation and proliferation in neuroblastoma
by: Amallia N. Setyawati, et al.
Published: (2014-12-01)